Day
[용어속성] Term
Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
ARDS 및 COVID-19 환자에서 덱사메타손의 효과 – 전향적, 다기관, 공개 라벨, 병렬 그룹, 무작위 대조 시험(REMED 시험): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] (C-reactive protein
24 hour
24 hours
administration
adrenal gland
Adult patients
Adverse
adverse events
age
alcohol
allergy
allocation
Antigen
ARDS
ARDS patients
ARMS
assumed
Barthel Index
benzyl alcohol
Berlin
Berlin criteria
Blinding
Block randomisation
Brazil
Breastfeeding
C-reactive protein
calculated
can be used
Cardiac arrest
Care
carried
case report form
CCI
Charlson Comorbidity Index
Chemotherapy
clinical
Comorbidity
comparator
completion
condition
conducted
consequence
Contraception
control group
Corticosteroid
Corticosteroids
COVID-19
COVID-19 ARDS patient
criteria
CRP
current
Czech Republic
Day
decision
defined
detect
Dexamethasone
dexamethasone 6 mg
diagnosed
dissemination
dose
doses
Dynamics
eCRF
Effect
Effectiveness
Efficacy and safety
electronic case report form
element
eligible
Endpoint
enrolled
enrolment
EudraCT
evaluate
event
expected
exploratory
Factor
followed by
French
gastrointestinal bleeding
HFNC
hospital
hospital discharge
Hospital stay
hypersensitivity
Hypothesis
ICU
ICU admission
ICUs
Identifier
Immunosuppression
immunosuppressive drug
immunosuppressive drugs
Independence
independent
independent of
Infection
infections
Inflammatory
infusion
intensive care unit
intensive care units
Intervention
intervention group
intractable
intravenously
intubate
intubation
investigational medicinal product
investigator
investigators
Laboratory
life
malignancy
marker
mechanical ventilation
medical history
moderate
moderate to severe
Mortality
nasal
nasal cannula
number
objective
observational study
once daily
Open-label
open-label trial
outcome
oxygen
Oxygen therapy
PaO
parallel-group
participant
Participation
Patient
patients with ARDS
patients with moderate
performed
power
power of 80%
Pragmatic
Pregnancy
present
primary efficacy endpoint
primary endpoint
protocol
Quality of life
randomisation
randomised
randomised controlled trial
receive
recruitment
Registered
routine clinical practice
RT-PCR
Sample size
scale
secondary
Secondary endpoints
Septic shock
sequence
severe ARDS
sexual abstinence
solution
Standard deviation
statistical analysis
statistician
status
Stratification
stratified
Study protocol
superinfection
supplementary material
systemic
systemic corticosteroids
thrombotic
Thrombotic complications
title
Treatment
treatment arm
Trial
Trial registration
two-sided
type I
type I error
university hospital
Ventilation
ventilator-free day
Ventilator-free days
Version
VFD
website
WHO
[DOI] 10.1186/s13063-021-05116-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05116-9 PMC 바로가기 [Article Type] Letter
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Infectious Disease
[키워드] accelerated
acute respiratory syndrome
affected
AGA
Androgen receptor
androgenetic alopecia
anti-androgen therapy
average
clinical
coronavirus
COVID-19
Day
defined
dependent on
double-blinded
drugs
expressed
female
female subject
inhibitor
less
men
Mild
moderate
Moderate COVID-19
Modification
Patient
patients treated
Placebo
positive
proxalutamide
Randomized
receptor
recruited
reduced
regulated
Remission
reported
Result
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 test
severe coronavirus disease
significantly
subject
subjects
the placebo group
time
TMPRSS2
transmembrane
transmembrane protease serine 2
treated
Treatment
Type II pneumocyte
viral clearance
viral spike protein
[DOI] 10.7759/cureus.13492 PMC 바로가기 [Article Type] Infectious Disease
[DOI] 10.7759/cureus.13492 PMC 바로가기 [Article Type] Infectious Disease
Diagnostic performance of COVID‐19 serological assays during early infection: A systematic review and meta‐analysis of 11 516 samples
초기 감염 중 COVID-19 혈청학적 검사의 진단 성능: 11 516개의 샘플에 대한 체계적인 검토 및 메타 분석
Meta-Analysis
[키워드] 95% CI
Accuracy
acute infection
adjust
antibody
CENTRAL
CLIA
Controlled
controlled trials
coronavirus disease
Coronavirus disease 2019
COVID‐19
COVID‐19
Day
determine
diagnose
Diagnosis
diagnostic
early infection
eligibility criteria
ELISA
English language
estimate
evaluate
for inclusion
human participant
ICA
IgG
IgM
IgM and IgG
Immunoglobulin
immunosorbent
Infection
objective
offer
outbreak
OVID
percentage
Result
SARS‐CoV‐2 infection
sensitivity
Sensitivity and specificity
Seroconversion
Serological assay
serological assays
Serological testing
serology
significantly higher
specificity
symptom onset
systematic review
unique
was performed
[DOI] 10.1111/irv.12841 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1111/irv.12841 PMC 바로가기 [Article Type] Meta-Analysis
Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study
Article
[키워드] 95% CI
acute respiratory distress
acute respiratory distress syndrome
analyzed
ARDS
benefit
Blood
Care
Combination
competing
confounder
coronavirus disease
COVID-19
Culture
cultures
Day
determine
dose
Effect
Efficacy
evaluate
hazard
hospital
Hospital mortality
hyperglycemia
incidence
inclusion criteria
increases in
inflammatory markers
Invasive mechanical ventilation
measurement
mechanical ventilation
median
Methylprednisolone
methylprednisolone group
moderate
multivariable
not differ
Organ failure
Patient
patients
patients with ARDS
positive
Primary outcome
Prone position
receive
regression analysis
respiratory
SARS-COV-2 infection
severe COVID-19
severity
significantly shorter
single-center study
Support
syndrome
the disease
Tocilizumab
Trial
two group
two groups
ventilator
ventilator-free day
Ventilator-free days
VFD
[DOI] 10.3390/jcm10040760 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/jcm10040760 PMC 바로가기 [Article Type] Article
Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: a single-center observational study from the first wave
도쿄의 중환자 COVID-19 환자의 임상 특성 및 결과: 첫 번째 물결의 단일 센터 관찰 연구
Observational Study
[키워드] Admission
age
analyzed
center
characteristic
Characteristics
clinical
Clinical course
clinically
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patient
Critically ill
Day
death
died
discharged
early phase
elevated
extracorporeal membrane oxygenation
Favipiravir
First wave
High dose
Hospital stay
ICU
In-hospital death
Inflammatory
intensive care
intensive care unit
Intubated
investigated
Japan
Japanese
Laboratory
laboratory finding
laboratory findings
Laboratory-confirmed COVID-19
lymphocyte
majority
male
marker
mechanical ventilation
median
median age
Methylprednisolone
Mortality
neutrophil
Neutrophil-to-lymphocyte ratio
observational study
on admission
one patient
outcome
oxygen
oxygen supplementation
pandemic
Patient
patients
peaked
receiving
reflected
Result
retrospective
single-center
Steroids
survival
survivor
Systemic steroid
systemic steroids
Tokyo
tracheostomy
trend
two patients
Ventilation
ventilator
was performed
was used
[DOI] 10.1186/s12879-021-05840-2 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1186/s12879-021-05840-2 PMC 바로가기 [Article Type] Observational Study
Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital
Medicine
[키워드] 95% CI
95% confidence interval
Acute kidney injury
AKI
APACHE II
APACHE II score
Brazil
Chinese
Clinical outcome
Cohort
COVID-19
COVID-19 pandemic
Day
death
Diagnosis
dialysis
discharge
elderly patients
European
evaluated
Factor
Hematuria
highest
hospitalized patient
ICU
ICU Patients
Improving
incidence
indicated
intensive care
KDIGO
Mortality
North
obesity
occurred
Patient
patients
patients hospitalized
prospective cohort
Public
renal replacement therapy
risk factor
Risk factors
severe COVID-19
severe disease
university hospital
with COVID-19
[DOI] 10.3389/fmed.2021.622577 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2021.622577 PMC 바로가기 [Article Type] Medicine
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial
COVID19에 감염된 종양-혈액학적 환자에서 호흡 부전 진행을 예방하기 위한 바리시티닙의 효능을 평가하기 위한 I/II상 임상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
AAK1
absence
activator
Acute respiratory failure
Administered
administration
Adverse
adverse events
affected
alkaline phosphatase
All participants
allergy
Alpha
alpha error
angina pectoris
Antibiotics
appearance
ARDS
Arm
assigned
AST/ALT
Baricitinib
baseline
beta error
Bilirubin
Blinding
Blood
Breastfeeding
can be used
candidate
Candidates
capture
Cardiac arrhythmia
carried
change
clearance
clinical
clinical condition
clinical suspicion
clinical trials
Coagulation
Cohort
Common Terminology Criteria
Comorbidity
Complete
completion
Compliance
congestive heart failure
control arm
Controlled trial
corticoid
Corticosteroids
COVID19
creatinine
creatinine clearance
CRP
D-dimer
Day
Deep venous thrombosis
description
Deterioration
Dexamethasone
dimer
discharge
discretion
disease
dissemination
diverticulitis
dose
dropout rate
Duration of therapy
ECMO
Efficacy
electronic case report form
element
eligibility criteria
Enrollment
evaluate
exclusion criteria
expected
experimental arm
extracorporeal membrane oxygenation
febrile neutropenia
ferritin
followed by
form
fraction
Gas exchange
greater
HBV
HCV
hemodynamic instability
High-flow nasal cannula
HIV
HIV infection
ICU
immobilization
immunological
impossibility
incidence
include
indication
Infection
infection with SARS-CoV-2
Inflammatory response
interfere
interferon
Interim
interim analysis
interleukin
interleukin 6
interstitial pneumonia
Intervention
intestinal perforation
Invasive mechanical ventilation
investigational agent
investigator
jak inhibitors
Jak-STAT
Laboratory
laboratory parameter
Laboratory parameters
LDH
less
limit
limits
management
mechanical ventilation
medical history
Medicine
meet
Methylprednisolone
Mild ARDS
Mortality
multi organ failure
nasal
nasal cannula
need for oxygen
neutropenia
neutrophil
Neutrophils
Non-invasive
number
objective
on mechanical ventilation
oncological patients
onset of symptom
open
open label
oral medication
organ dysfunction
Organ failure
outcome
oxygen
oxygen support
PaFi
participant
Participants
Participation
pathogen
Pathogens
pathway
Patient
patients
performance status
performed
phase
Phase 1
Phase 2
Phase I
phosphatase
platform
Pneumonia
poor prognosis
positive
Prednisone
pregnancy test
pregnant
prejudice
Prevent
progression
Prophylaxis
Protein
protein kinase
protocol
Psychiatric
psychiatric illness
Pulmonary embolism
radiological
randomisation
randomised
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receptor
recruitment
REDCap
REDcap platform
reduce
reduced
Remdesivir
removal
report
reported
required
respiratory
Respiratory failure
Respiratory function
respiratory insufficiency
respiratory tract
Sample size
SARS-CoV-2
SARS-CoV2
SARS-CoV2 infection
Secondary objectives
Sepsis
severe adverse event
severe adverse events
severe pneumonia
severe respiratory failure
Spain
Spanish
Standard of care
STAT
status
study enrollment
Study protocol
supplemental oxygen requirement
supplemental oxygen requirements
supplementary material
Support
surgical
surgical intervention
Symptom
symptomatic
Tablet
Therapies
therapy
thromboembolic disease
thrombosis
Tocilizumab
total bilirubin
Toxicity
Transcription
transducer
Treatment
treatment period
Trial
unstable angina
use of corticosteroid
Venous thrombosis
Version
viral endocytosis
website
Withdrawal
worsening
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter
Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan
일본의 코로나19 증상에 대한 항SARS-CoV-2 IgM 및 IgG 항체의 민감도 및 특이도의 시간 경과
Article
[키워드] anti-SARS-CoV-2 IgM
Antibody test
antibody tests
chemiluminescent immunoassay
CLIA
coated with
coronavirus
Coronavirus infection
coronavirus infection disease
Course
COVID-19
COVID-19 patients
Cutoff
cutoff value
Day
diagnosis of COVID-19
diagnosis of SARS-CoV-2
Diagnostic markers
disease onset
Diseases
evaluate
IgG
IgG antibody
IgG test
IgG titers
IgM
IgM and IgG
Infection
Infectious diseases
Japan
less
magnetic bead
Magnetic beads
much higher
patient population
Protein
reported
required
respiratory
respiratory syndrome coronavirus
ROC analysis
SARS-CoV-2
SARS-CoV-2 IgM
SARS-COV-2 infection
SARS-CoV-2 nucleocapsid
sensitivity
Sensitivity and specificity
sera
Spike protein
subjects
suggested
symptom onset
symptomatic
the SARS-CoV-2
time
titers
Treatment
[DOI] 10.1038/s41598-021-82428-5 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-021-82428-5 PMC 바로가기 [Article Type] Article
COVID-19 and emergencies in patients with diabetes: two case reports
Case Report
[키워드] Acute kidney injury
Asian
Case report
close monitoring
Complication
condition
conditions
Coronavirus disease 2019
COVID-19
COVID-19 patient
Day
death
diabete
diabetes
Diabetic
Diabetic emergencies
diabetic ketoacidosis
diabetic patient
Hyperosmolar hyperglycemic state
incidence
insulin
intensive care
intravenous fluid
Maldive
male
Mild
mortality rate
outcome
pandemic
Patient
patients
poor prognosis
positive
precipitated
Prevent
reported
shown
with COVID-19
[DOI] 10.1186/s13256-020-02659-4 PMC 바로가기 [Article Type] Case Report
[DOI] 10.1186/s13256-020-02659-4 PMC 바로가기 [Article Type] Case Report